Viking Therapeutics stock debate

What happened: Viking Therapeutics' (NASDAQ: VKTX) stock has been volatile recently. The company is developing weight loss drugs, with its lead candidate, VK2735, in late-stage trials. One analyst predicts VKTX could soar 188% due to the growing obesity drug market, expected to reach $150 billion by 2035. However, competition from giants like Eli Lilly and Novo Nordisk, and the need for successful Phase 3 trials, pose challenges.

Market impact: The biotech sector, specifically obesity drug developers, is affected. Investor sentiment towards VKTX is mixed, with some bullish on its growth potential and others cautious due to competition and trial uncertainties. The success of VK2735 could drive demand for similar drugs, benefiting the sector, while failure could dampen investor enthusiasm.

What to watch next: VKTX's Phase 3 trial results for VK2735 are crucial. The company is expected to report top-line data in the second half of 2023. Additionally, any regulatory updates regarding VK2735's approval path will significantly influence the narrative. Lastly, watch for any strategic partnerships or licensing deals that could bolster VKTX's position in the market.